In this video entry, David and Austin focus on InterMune, which has shorts pouring in after a tough launch for Esbriet. Is it time to invest in this cutting-edge company on the cheap, or is the poor month a sign of further troubles ahead? Watch and find out.
Many investors are attracted to InterMune and biotechs like it, since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
The article Are the Shorts Wrong About InterMune? originally appeared on Fool.com.
Dave Williamson, Austin Smith, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.